Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Ayca Gucalp(Institute of Cancer Research), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Mary Ellen Moynahan(Memorial Sloan Kettering Cancer Center), Minetta C. Liu(Mayo Clinic), Lamia F. Momen(Memorial Sloan Kettering Cancer Center), Andres Forero(University of Alabama at Birmingham), Clifford A. Hudis(American Society of Clinical Oncology), Ashley S. Doane, Lisa A. Carey(University of North Carolina at Chapel Hill), Kimberly Feigin(Memorial Sloan Kettering Cancer Center), Vered Stearns(Johns Hopkins University), Sara M. Tolaney(Harvard University), James N. Ingle(Mayo Clinic), Hope S. Rugo(City of Hope), Sujata Patil(Dr. D. Y. Patil Medical College, Hospital and Research Centre), Joseph M. Gonzalez(Memorial Sloan Kettering Cancer Center), Michael A. Danso, Dilip D. Giri(Memorial Sloan Kettering Cancer Center), Kimberly Blackwell(Duke University), Steven J. Isakoff(Harvard University), Arooj Akhtar(Memorial Sloan Kettering Cancer Center), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center)
Cited by 744
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k